Lineage Cell Therapeutics, Inc. (TLV: LCTX)
Israel
· Delayed Price · Currency is ILS · Price in ILA317.90
-6.10 (-1.88%)
Oct 15, 2024, 5:24 PM IDT
Lineage Cell Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 6.19 | 8.95 | 14.7 | 4.34 | 1.83 | 3.52 | Upgrade
|
| Revenue Growth (YoY) | -41.22% | -39.16% | 238.70% | 137.73% | -48.05% | -29.53% | Upgrade
|
| Cost of Revenue | -1.61 | 0.67 | 0.73 | 1.43 | 0.39 | 0.41 | Upgrade
|
| Gross Profit | 7.8 | 8.27 | 13.98 | 2.92 | 1.44 | 3.1 | Upgrade
|
| Selling, General & Admin | 14.16 | 13.77 | 22.51 | 18.21 | 15.57 | 18.93 | Upgrade
|
| Research & Development | 15.71 | 15.71 | 13.99 | 33.91 | 12.32 | 17.95 | Upgrade
|
| Operating Expenses | 29.86 | 29.48 | 36.5 | 52.13 | 27.89 | 36.88 | Upgrade
|
| Operating Income | -22.07 | -21.2 | -22.52 | -49.21 | -26.45 | -33.78 | Upgrade
|
| Interest & Investment Income | 1.76 | 1.63 | 0.83 | 0 | 1.04 | 1.51 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.26 | -0.5 | -2 | 1.49 | 2.88 | 2.53 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.03 | -0 | 0.07 | 0.21 | -0.17 | 0.78 | Upgrade
|
| EBT Excluding Unusual Items | -20.59 | -20.08 | -23.62 | -47.52 | -22.7 | -28.95 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | - | -5.1 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.08 | -0.18 | -2.19 | 3.73 | 0.78 | 14.81 | Upgrade
|
| Legal Settlements | -3.53 | -3.53 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | 0.5 | - | 0.52 | - | - | Upgrade
|
| Pretax Income | -24.2 | -23.28 | -25.81 | -43.27 | -21.92 | -19.23 | Upgrade
|
| Income Tax Expense | - | -1.8 | 0.54 | - | -1.24 | -7.41 | Upgrade
|
| Earnings From Continuing Operations | -24.2 | -21.48 | -26.35 | -43.27 | -20.69 | -11.83 | Upgrade
|
| Minority Interest in Earnings | 0.02 | -0.01 | 0.08 | 0.25 | 0.04 | 0.12 | Upgrade
|
| Net Income | -24.19 | -21.49 | -26.27 | -43.02 | -20.65 | -11.71 | Upgrade
|
| Net Income to Common | -24.19 | -21.49 | -26.27 | -43.02 | -20.65 | -11.71 | Upgrade
|
| Shares Outstanding (Basic) | 180 | 173 | 170 | 165 | 150 | 146 | Upgrade
|
| Shares Outstanding (Diluted) | 180 | 173 | 170 | 165 | 150 | 146 | Upgrade
|
| Shares Change (YoY) | 6.05% | 1.69% | 3.22% | 9.64% | 3.10% | 14.68% | Upgrade
|
| EPS (Basic) | -0.13 | -0.12 | -0.15 | -0.26 | -0.14 | -0.08 | Upgrade
|
| EPS (Diluted) | -0.13 | -0.12 | -0.15 | -0.26 | -0.14 | -0.08 | Upgrade
|
| Free Cash Flow | -22.33 | -29.24 | 0.65 | -23.9 | -19.82 | -32.39 | Upgrade
|
| Free Cash Flow Per Share | -0.12 | -0.17 | 0.00 | -0.15 | -0.13 | -0.22 | Upgrade
|
| Gross Margin | 126.08% | 92.50% | 95.05% | 67.15% | 78.92% | 88.28% | Upgrade
|
| Operating Margin | -356.69% | -237.04% | -153.17% | -1133.63% | -1448.36% | -960.91% | Upgrade
|
| Profit Margin | -391.00% | -240.20% | -178.69% | -990.99% | -1130.83% | -333.12% | Upgrade
|
| Free Cash Flow Margin | -361.02% | -326.89% | 4.39% | -550.59% | -1085.27% | -921.39% | Upgrade
|
| EBITDA | -21.4 | -20.51 | -21.79 | -48.34 | -24.41 | -30.78 | Upgrade
|
| EBITDA Margin | - | -229.30% | -148.22% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.67 | 0.69 | 0.73 | 0.87 | 2.04 | 3 | Upgrade
|
| EBIT | -22.07 | -21.2 | -22.52 | -49.21 | -26.45 | -33.78 | Upgrade
|
| EBIT Margin | - | -237.04% | -153.17% | - | - | - | Upgrade
|
| Revenue as Reported | 6.19 | 8.95 | 14.7 | 4.34 | 1.83 | 3.52 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.